Yen Kristen 4

What Happened
Kristen Yen, SVP Global Clinical Operations and Patient Advocacy at Soleno Therapeutics (SLNO), received two RSU awards on January 21, 2026 totaling 22,300 restricted stock units (10,400 and 11,900). Both awards were reported as acquisitions at $0.00 per share (no cash paid). The 11,900 RSUs are reported as a derivative award (contingent right to receive shares).

Key Details

• Transaction date: 2026-01-21; reported on Form 4 filed 2026-01-23 (timely filing).
• Amounts: 10,400 RSUs (A) and 11,900 RSUs (A, derivative) — total 22,300 RSUs; price reported $0.00; total purchase value $0.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes of note:
  • F1: The 10,400 RSUs represent contingent rights to one share per RSU; 100% vest on December 15, 2027 subject to continued service.
  • F2: Certain securities are RSUs subject to applicable vesting schedules/conditions.
  • F3: Describes a separate option vesting schedule (1/48th monthly starting Feb 1, 2026) — appears to refer to other awards, not these RSUs.
• Filing timeliness: Filed within the typical 2-business-day Form 4 window; not marked late.

Context
RSUs are grants that convert to actual shares only if vesting conditions are met; a “derivative” RSU here simply means a contingent right to receive common stock later. This filing reports an award (grant), not a purchase or sale, so it does not reflect an immediate cash investment or disposition.